Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics (NASDAQ: ARTV) has reported its full year 2024 financial results and business updates. The company ended 2024 with $185.4 million in cash and investments, expected to fund operations through 2026. This includes $179.0 million raised from their July 2024 IPO.
Key financial metrics show a net loss of $65.4 million for 2024, compared to a net income of $28.7 million in 2023. R&D expenses remained stable at $50.3 million, while G&A expenses increased to $17.2 million from $13.9 million in 2023. Collaboration revenue dropped to zero from $32.9 million in 2023.
The company expects to share initial data for AlloNK® from their autoimmune program in H1 2025, along with updated clinical data from their Phase 1/2 trial exploring AlloNK + rituximab in NHL. Artiva has strengthened its leadership team with expertise in cell therapy and autoimmune disease, including the appointment of Dr. Dan Baker to the Board of Directors.
Artiva Biotherapeutics (NASDAQ: ARTV) ha riportato i risultati finanziari e gli aggiornamenti aziendali per l'intero anno 2024. L'azienda ha chiuso il 2024 con 185,4 milioni di dollari in contante e investimenti, previsti per finanziare le operazioni fino al 2026. Questo include 179,0 milioni di dollari raccolti dalla loro IPO di luglio 2024.
I principali indicatori finanziari mostrano una perdita netta di 65,4 milioni di dollari per il 2024, rispetto a un utile netto di 28,7 milioni di dollari nel 2023. Le spese per R&S sono rimaste stabili a 50,3 milioni di dollari, mentre le spese generali e amministrative sono aumentate a 17,2 milioni di dollari rispetto ai 13,9 milioni di dollari del 2023. I ricavi da collaborazioni sono scesi a zero rispetto ai 32,9 milioni di dollari del 2023.
L'azienda prevede di condividere dati iniziali per AlloNK® dal loro programma autoimmune nel primo semestre del 2025, insieme ai dati clinici aggiornati dal loro trial di Fase 1/2 che esplora AlloNK + rituximab nel NHL. Artiva ha rafforzato il suo team dirigenziale con esperti in terapia cellulare e malattie autoimmuni, inclusa la nomina del Dr. Dan Baker nel Consiglio di Amministrazione.
Artiva Biotherapeutics (NASDAQ: ARTV) ha informado sobre sus resultados financieros y actualizaciones comerciales para el año completo 2024. La compañía terminó 2024 con 185.4 millones de dólares en efectivo e inversiones, que se espera financien las operaciones hasta 2026. Esto incluye 179.0 millones de dólares recaudados en su OPI de julio de 2024.
Los principales indicadores financieros muestran una pérdida neta de 65.4 millones de dólares para 2024, en comparación con una ganancia neta de 28.7 millones de dólares en 2023. Los gastos de I+D se mantuvieron estables en 50.3 millones de dólares, mientras que los gastos generales y administrativos aumentaron a 17.2 millones de dólares desde 13.9 millones de dólares en 2023. Los ingresos por colaboraciones cayeron a cero desde 32.9 millones de dólares en 2023.
La compañía espera compartir datos iniciales para AlloNK® de su programa autoinmune en la primera mitad de 2025, junto con datos clínicos actualizados de su ensayo de Fase 1/2 que explora AlloNK + rituximab en NHL. Artiva ha fortalecido su equipo directivo con experiencia en terapia celular y enfermedades autoinmunes, incluida la designación del Dr. Dan Baker en la Junta Directiva.
Artiva Biotherapeutics (NASDAQ: ARTV)는 2024년 전체 재무 결과 및 비즈니스 업데이트를 보고했습니다. 이 회사는 2024년을 1억 8540만 달러의 현금 및 투자로 마감했으며, 이는 2026년까지 운영 자금을 지원할 것으로 예상됩니다. 여기에는 2024년 7월 IPO에서 모금한 1억 7900만 달러가 포함됩니다.
주요 재무 지표에 따르면 2024년 순손실은 6540만 달러로, 2023년의 순이익 2870만 달러와 비교됩니다. 연구개발(R&D) 비용은 5030만 달러로 안정세를 유지했으며, 일반 관리(G&A) 비용은 2023년 1390만 달러에서 1720만 달러로 증가했습니다. 협력 수익은 2023년 3290만 달러에서 제로로 감소했습니다.
회사는 2025년 상반기에 자가면역 프로그램의 AlloNK® 초기 데이터를 공유할 것으로 예상하며, NHL에서 AlloNK + rituximab을 탐색하는 1/2상 시험의 업데이트된 임상 데이터도 함께 제공할 예정입니다. Artiva는 세포 치료 및 자가면역 질환에 대한 전문성을 갖춘 리더십 팀을 강화했으며, Dan Baker 박사를 이사회에 임명했습니다.
Artiva Biotherapeutics (NASDAQ: ARTV) a publié ses résultats financiers et ses mises à jour commerciales pour l'année complète 2024. L'entreprise a terminé 2024 avec 185,4 millions de dollars en liquidités et investissements, prévus pour financer ses opérations jusqu'en 2026. Cela inclut 179,0 millions de dollars levés lors de leur introduction en bourse de juillet 2024.
Les principaux indicateurs financiers montrent une perte nette de 65,4 millions de dollars pour 2024, contre un bénéfice net de 28,7 millions de dollars en 2023. Les dépenses de R&D sont restées stables à 50,3 millions de dollars, tandis que les dépenses générales et administratives ont augmenté à 17,2 millions de dollars contre 13,9 millions de dollars en 2023. Les revenus de collaboration ont chuté à zéro contre 32,9 millions de dollars en 2023.
L'entreprise prévoit de partager des données initiales pour AlloNK® de son programme auto-immun au premier semestre 2025, ainsi que des données cliniques mises à jour de son essai de phase 1/2 explorant AlloNK + rituximab dans le NHL. Artiva a renforcé son équipe de direction avec une expertise en thérapie cellulaire et en maladies auto-immunes, y compris la nomination du Dr Dan Baker au conseil d'administration.
Artiva Biotherapeutics (NASDAQ: ARTV) hat seine Finanzzahlen und Unternehmensupdates für das gesamte Jahr 2024 veröffentlicht. Das Unternehmen schloss das Jahr 2024 mit 185,4 Millionen Dollar in Bar- und Investitionsmitteln ab, was voraussichtlich die Betriebstätigkeiten bis 2026 finanzieren wird. Dies umfasst 179,0 Millionen Dollar, die bei ihrem IPO im Juli 2024 gesammelt wurden.
Wichtige Finanzkennzahlen zeigen einen Nettoverlust von 65,4 Millionen Dollar für 2024, im Vergleich zu einem Nettogewinn von 28,7 Millionen Dollar im Jahr 2023. Die F&E-Ausgaben blieben stabil bei 50,3 Millionen Dollar, während die allgemeinen und administrativen Ausgaben von 13,9 Millionen Dollar im Jahr 2023 auf 17,2 Millionen Dollar anstiegen. Die Einnahmen aus Kooperationen sanken auf null von 32,9 Millionen Dollar im Jahr 2023.
Das Unternehmen plant, erste Daten zu AlloNK® aus seinem Autoimmunprogramm im ersten Halbjahr 2025 zu teilen, zusammen mit aktualisierten klinischen Daten aus seiner Phase-1/2-Studie, die AlloNK + Rituximab bei NHL untersucht. Artiva hat sein Führungsteam mit Experten für Zelltherapie und Autoimmunerkrankungen verstärkt, einschließlich der Ernennung von Dr. Dan Baker in den Vorstand.
- Strong cash position of $185.4M, funding operations through 2026
- Successful IPO raising $179.0M in July 2024
- Expansion of leadership team with industry experts
- Multiple clinical trials progressing with data readouts expected in 2025
- Net loss increased to $65.4M in 2024 from net income of $28.7M in 2023
- Collaboration revenue dropped to zero from $32.9M in previous year
- G&A expenses increased by 23.7% to $17.2M
Insights
Artiva's full-year 2024 results reveal a significant financial transition for this early-stage cell therapy player. The company experienced a complete loss of collaboration revenue, dropping from
The silver lining is Artiva's robust cash position. Following its July 2024 IPO that raised
Artiva's strategic leadership additions, focused on autoimmune disease expertise, align with its clinical development priorities and suggest confidence in advancing its pipeline. The company now faces the challenge of delivering compelling clinical data from its NHL and autoimmune programs in 2025 to validate its AlloNK® platform before requiring additional funding in late 2026.
Artiva's AlloNK® cell therapy platform is approaching a critical inflection point with multiple data readouts scheduled for H1 2025. The company is pursuing a dual-pathway strategy targeting both cancer and autoimmune indications, which is scientifically intriguing but carries execution risks.
For its non-Hodgkin lymphoma program, management's characterization of the data as "one of the strongest data sets for the allogeneic field" highlights deep B-cell depletion with durable responses. Most notably, the compatibility with outpatient administration could provide a significant competitive advantage over autologous CAR-T therapies that typically require hospitalization.
In autoimmune diseases, Artiva is targeting high-value indications including systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis, and several rare autoimmune conditions. The combination approach with rituximab or obinutuzumab suggests a mechanistic focus on comprehensive B-cell depletion through complementary pathways. The company's strategic hiring of executives with autoimmune disease experience from Kyverna, Horizon, and IGM Biosciences indicates a serious commitment to this therapeutic area.
With expanded leadership including Dan Baker (formerly of Johnson & Johnson's immunology R&D), Artiva has assembled expertise specifically aligned with its clinical focus areas. The upcoming data will be crucial in determining whether their allogeneic NK cell approach can deliver meaningful clinical benefits with improved safety and accessibility compared to existing therapies.
Initial data for AlloNK® from autoimmune program expected H1 2025
Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025
Strengthened key leadership with cell therapy and autoimmune expertise across organization
Robust balance sheet with cash, cash equivalents and investments of
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress.
“2024 was a transformational year for Artiva including initiating dosing of AlloNK® in patients with autoimmune disease across our trials, a successful initial public offering strengthening our balance sheet, and expanding key leadership across the organization with expertise in cell therapy and autoimmune disease,” said Fred Aslan, M.D., CEO of Artiva. “We look forward to sharing initial data from our AlloNK® program in autoimmune disease this year. We also look forward to sharing updated clinical data from our non-Hodgkin’s lymphoma (NHL) trial with AlloNK® which continues to mature as one of the strongest data sets for the allogeneic field, demonstrating deep B-cell depletion, continued durability of response, and the compatibility of our treatment regimen with outpatient administration.”
Recent Business Highlights
Corporate and Financial Updates
- Expanded Board of Directors: In January 2025, Artiva appointed Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) most recently as the Vice President of Immunology R&D.
- Bolstered Key Development Leadership: Artiva appointed key leadership with cell therapy and autoimmune expertise across the development organization, including Benjamin Dewees as Senior Vice President (SVP), Regulatory Affairs, David Moriarty, Ph.D., as SVP, Clinical Operations, and Feng Xu as SVP, Biometrics. Collectively, the leadership team brings experience developing therapies targeting autoimmune indications including systemic lupus erythematosus (SLE), lupus nephritis (LN), rheumatoid arthritis (RA) and Sjogren’s disease from their tenures at companies such as Kyverna Therapeutics, Inc., Horizon Therapeutics plc and IGM Biosciences, Inc.
Upcoming Milestones
- Initial data for AlloNK® (also known as AB-101) on autoimmune indications from at least one of the following trials expected in H1 2025:
- Artiva Sponsored Trial in SLE / LN: Ongoing Phase 1/1b trial evaluating AlloNK® in combination with rituximab or obinutuzumab in patients with SLE with or without LN.
- Ongoing IIT Basket Trial: Investigator-initiated basket trial (IIT) assessing the safety, tolerability, and clinical activity of AlloNK® plus rituximab in patients with RA, pemphigus vulgaris, granulomatosis with polyangiitis/microscopic polyangiitis, and SLE. The trial is being conducted by Integral Rheumatology & Immunology Specialists, a community rheumatology clinic.
- Updated clinical data from the Phase 1/2 trial exploring AlloNK® + rituximab in patients with relapsed/refractory B-cell NHL showing continued durability of response to be presented at a medical conference in 2025
Full Year 2024 Financial Results
- Cash, Cash Equivalents and Investments. As of December 31, 2024, Artiva had cash, cash equivalents, and investments of
$185.4 million . This includes$179.0 million in gross proceeds from Artiva’s completed initial public offering in July 2024 in which it sold 14,920,000 shares of its common stock, including partial exercise of the overallotment option. Existing cash, cash equivalents, and investments as of December 31, 2024, are expected to fund operations at least through the end of 2026. - Collaboration Revenue. Collaboration revenue was zero for the year ended December 31, 2024, compared to
$32.9 million for the year ended December 31, 2023. - Research and Development Expenses. Research and development expenses were
$50.3 million for each of the years ended December 31, 2024 and 2023. - General and Administrative Expenses. General and administrative expenses were
$17.2 million for the year ended December 31, 2024, compared to$13.9 million for the year ended December 31, 2023. - Other Income, net. Other income, net, was
$1.9 million for the year ended December 31, 2024, compared to other income, net, of$2.0 million for the year ended December 31, 2023. - Net Loss. Net loss totaled
$65.4 million for the year ended December 31, 2024, as compared to net income of$28.7 million for the year ended December 31, 2023, with non-cash stock-based compensation expense of$7.0 million and$7.1 million for the years ended December 31, 2024 and 2023, respectively.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva Biotherapeutics, Inc. (the “Company”) regarding the potential benefits, accessibility, effectiveness and safety of AlloNK®; the Company’s ability to advance AlloNK® in autoimmune disease; the Company’s expectations regarding timing and availability of data from the Company’s clinical trials or the IIT; the Company’s future results of operations and financial position, including cash runway; and the Company’s presentation plans. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
| Artiva Biotherapeutics, Inc. Condensed Balance Sheets (unaudited) (in thousands) | |||||||
| December 31, 2024 | December 31, 2023 | ||||||
| Assets | |||||||
| Cash, cash equivalents and investments | $ | 185,428 | $ | 76,971 | |||
| Property and equipment, net | 6,370 | 8,096 | |||||
| Operating and financing lease right-of-use assets | 14,055 | 16,547 | |||||
| Other assets | 3,728 | 3,500 | |||||
| Total assets | $ | 209,581 | $ | 105,114 | |||
| Liabilities, convertible preferred stock, and stockholders' equity (deficit) | |||||||
| Accounts payable and accrued expenses | $ | 8,513 | $ | 8,631 | |||
| Operating and financing lease liabilities | 14,354 | 16,912 | |||||
| Simple agreements for future equity (SAFEs) | — | 25,100 | |||||
| Other liabilities | 73 | 73 | |||||
| Total liabilities | 22,940 | 50,716 | |||||
| Convertible preferred stock | — | 216,413 | |||||
| Stockholders' equity (deficit) | 186,641 | (162,015 | ) | ||||
| Total liabilities, convertible preferred stock, and stockholders' equity (deficit) | $ | 209,581 | $ | 105,114 | |||
| Artiva Biotherapeutics, Inc. Condensed Statements of Operation and Comprehensive Loss (unaudited) (in thousands, except share and per share data) | ||||||||
| Year Ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | ||||||||
| Collaboration revenue | $ | — | $ | 32,923 | ||||
| License and development support revenue | 251 | 569 | ||||||
| Total revenue | 251 | 33,492 | ||||||
| Operating expenses: | ||||||||
| Research and development | 50,328 | 50,251 | ||||||
| General and administrative | 17,205 | 13,912 | ||||||
| Total operating expenses | 67,533 | 64,163 | ||||||
| Loss from operations | (67,282 | ) | (30,671 | ) | ||||
| Other income, net | ||||||||
| Interest income | 5,349 | 2,535 | ||||||
| Change in fair value of SAFEs | (3,597 | ) | (707 | ) | ||||
| Other income, net | 157 | 195 | ||||||
| Total other income, net | 1,909 | 2,023 | ||||||
| Loss before provision for income taxes | (65,373 | ) | (28,648 | ) | ||||
| Provision for income taxes | — | (72 | ) | |||||
| Net loss | $ | (65,373 | ) | $ | (28,720 | ) | ||
| Net loss per share, basic and diluted | $ | (5.81 | ) | $ | (35.78 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 11,258,851 | 802,747 | ||||||
| Comprehensive loss: | ||||||||
| Net loss | $ | (65,373 | ) | $ | (28,720 | ) | ||
| Other comprehensive income (loss) | (437 | ) | 308 | |||||
| Comprehensive loss | $ | (65,810 | ) | $ | (28,412 | ) | ||
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
Source: Artiva Biotherapeutics, Inc.
FAQ
What are the key financial results for Artiva Biotherapeutics (ARTV) in 2024?
When will ARTV release initial data for its AlloNK autoimmune program?
How much did ARTV raise in their 2024 IPO?
How long will ARTV's current cash position fund operations?
What clinical trials is ARTV currently conducting with AlloNK?
